{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:46:39Z","timestamp":1778813199183,"version":"3.51.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.euroneuro.2014.03.012","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T20:37:36Z","timestamp":1396643856000},"page":"1046-1055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs"],"prefix":"10.1016","volume":"24","author":[{"given":"Myrto T.","family":"Samara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Helfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.03.012_bib1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.socscimed.2005.01.004","article-title":"A comparative analysis of drug safety withdrawals in the UK and the US (1971\u20131992): implications for current regulatory thinking and policy","volume":"61","author":"Abraham","year":"2005","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib2","doi-asserted-by":"crossref","unstructured":"Adams, C.E., Awad, G., Rathbone, J., Thornley, B., 2007. Chlorpromazine versus placebo for schizophrenia. The Cochrane database of systematic reviews, CD000284.","DOI":"10.1002\/14651858.CD000284.pub2"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib3","doi-asserted-by":"crossref","unstructured":"Ahmed, U., Jones, H., Adams, C.E., 2010. Chlorpromazine for psychosis induced aggression or agitation. The Cochrane database of systematic reviews, CD007445.","DOI":"10.1002\/14651858.CD007445.pub2"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib4","first-page":"20","article-title":"A standard-controlled clinical study with benzquinamide in the treatment of chronic schizophrenic patients","volume":"13","author":"Amin","year":"1977","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib5","unstructured":"AstraZeneca, 2000. A multicentre, double-blind, randomised trial to compare the effects of SEROQUEL and chlorpromazine in patients with treatment resistant schizophrenia (5077IL\/0054 [TRESS])."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib6","unstructured":"AstraZeneca, 2005. A multicentre, double-blind, randomised comparison of quetiapine (SEROQUEL) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia (5077IL\/0031)."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3736\/jcim20060204","article-title":"Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology","volume":"4","author":"Bian","year":"2006","journal-title":"J. Chin. Integr. Med."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","article-title":"Multiple significance tests: the Bonferroni method","volume":"310","author":"Bland","year":"1995","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0032-1305335","article-title":"[Including or excluding data: intention-to-treat and completer analyses]. Daten ein- oder ausschlieSSen: intention-to-treat- und Completer-Analysen","volume":"62","author":"Bohnke","year":"2012","journal-title":"Psychother Psychosom. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib11","series-title":"Comprehensive Meta-Analysis","author":"Borenstein","year":"2005"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1979.tb00259.x","article-title":"Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study","volume":"60","author":"Bratfos","year":"1979","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib13","series-title":"Comprehensive Textbook of Psychiatry","article-title":"Schizophrenia","author":"Buchanan","year":"2000"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib15","series-title":"Review Manager (RevMan)","author":"Centre","year":"2012"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/schbul\/17.2.217","article-title":"When symptoms persist: choosing among alternative somatic treatments for schizophrenia","volume":"17","author":"Christison","year":"1991","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia","volume":"155","author":"Conley","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bmj.316.7136.989","article-title":"When can odds ratios mislead?","volume":"316","author":"Davies","year":"1998","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib19","series-title":"Comprehensive Textbook of Psychiatry","first-page":"1591","article-title":"Antipsychotic drugs","author":"Davis","year":"1989"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Tr."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2014.03.012_bib22","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0920-9964(12)70787-9","article-title":"Is haloperidol more effective than other first-generation antipsychotics in schizophrenia? A meta-analysis of randomized controlled trials","volume":"136","author":"Dold","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(97)02419-7","article-title":"Language bias in randomised controlled trials published in English and German","volume":"350","author":"Egger","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1192\/bjp.105.439.349","article-title":"A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis","volume":"105","author":"Fleming","year":"1959","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.schres.2010.10.016","article-title":"Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials","volume":"126","author":"Furukawa","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.schres.2005.07.007","article-title":"Clotiapine compared with chlorpromazine in chronic schizophrenia","volume":"80","author":"Geller","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0895-4356(94)00098-B","article-title":"Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?","volume":"48","author":"Gregoire","year":"1995","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib30","doi-asserted-by":"crossref","unstructured":"Guaiana, G., Barbui, C., Hotopf, M., 2007. Amitriptyline for depression. The Cochrane database of systematic reviews, CD004186.","DOI":"10.1002\/14651858.CD004186.pub2"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib31","unstructured":"Guy, W., 1976. Clinical Global Impressions, ECDEU Assessment Manual for Psychopharmacology \u2013 Revised (DHEW Publ No ADM 76-338), Revised DHEW ed. Rockville, Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, pp. 218\u2013222."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1192\/bjp.106.442.40","article-title":"A controlled trial of thiopropazate dihydrochloride (dartalan), chlorpromazine and occupational therapy in chronic schizophrenics","volume":"106","author":"Hamilton","year":"1960","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib33","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004850-199705000-00001","article-title":"A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia","volume":"12","author":"Hong","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib35","first-page":"77","article-title":"Clozapine antipsychotic activity in treatment-resistant schizophrenics","volume":"1","author":"Honigfeld","year":"1984","journal-title":"Adv. Therapy"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v60n0109","article-title":"The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia","volume":"60","author":"Howanitz","year":"1999","journal-title":"J.Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib38","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia","volume":"21","author":"Kane","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2011.143","article-title":"Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics","volume":"18","author":"Kishimoto","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib43","series-title":"Diagnosis and Drug Treatment of Psychiatric Disorders","author":"Klein","year":"1969"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib44","first-page":"271","article-title":"Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial","volume":"31","author":"Lal","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib45","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second ed.","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/schbul\/sbn035","article-title":"Implications of clinical trial design on sample size requirements","volume":"34","author":"Leon","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib47","doi-asserted-by":"crossref","unstructured":"Leucht, C., Kitzmantel, M., Chua, L., Kane, J., Leucht, S., 2008. Haloperidol versus chlorpromazine for schizophrenia. The Cochrane Database of Systematic Reviews, CD004278.","DOI":"10.1002\/14651858.CD004278.pub2"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib50","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u05f3response\u05f3 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib51","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1300873","article-title":"The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacol.: Official Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.euroneuro.2011.11.007","article-title":"Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area","volume":"22","author":"Leucht","year":"2012","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"Br. J. Psychiatry: the J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib55","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib56","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI","volume":"98","author":"Levine","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib57","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib58","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib59","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib60","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"Br. J. Psychiatry: J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1192\/bjp.131.3.310","article-title":"High dosage haloperidol in chronic schizophrenia","volume":"131","author":"McCreadie","year":"1977","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/026988119701100411","article-title":"A study of enhanced management in patients with treatment-resistant schizophrenia","volume":"11","author":"Mercer","year":"1997","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(96)90538-3","article-title":"Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews","volume":"347","author":"Moher","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib66","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib67","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0895-4356(00)00188-8","article-title":"What contributions do languages other than English make on the results of meta-analyses?","volume":"53","author":"Moher","year":"2000","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib68","first-page":"367","article-title":"A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia","volume":"11","author":"Neal","year":"1969","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","article-title":"A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"96","author":"Peuskens","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/070674376501000104","article-title":"Comparative study of butaperazine and prochlorperazine in chronic schizophrenia","volume":"10","author":"Rajotte","year":"1965","journal-title":"Can. Psychiatr. Assoc. J."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib72","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1176\/ajp.114.12.1077","article-title":"A controlled study of the short-term differential treatment of schizophrenia","volume":"114","author":"Simon","year":"1958","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib73","series-title":"11. Antipsychotic Agents, Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2000"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib74","series-title":"Stata Statistical Software: Release 12","author":"StataCorp","year":"2011"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib75","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib76","series-title":"R: A Language and Environment for Statistical Computing","author":"Team","year":"2012"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib77","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.317.7167.1181","article-title":"Content and quality of 2000 controlled trials in schizophrenia over 50 years","volume":"317","author":"Thornley","year":"1998","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib78","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/j.1552-4604.1972.tb00166.x","article-title":"A double-blind comparison of sulpiride with chlorpromazine in chronic schizophrenia","volume":"12","author":"Toru","year":"1972","journal-title":"J. Clin. Pharmacol. New Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib79","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","article-title":"Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time","volume":"57","author":"Trikalinos","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib80","unstructured":"WHO, World Health Organization Model List of Essential Medicines, 17th list (March 2011)."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib81","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1192\/bjp.107.446.90","article-title":"A double-blind trial to investigate the effects of thorazine (largactil, chlorpromazine), compazine (stemetil, prochlorperazine) and stelazine (trifluoperazine) in paranoid schizophrenia","volume":"107","author":"Wilson","year":"1961","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.euroneuro.2014.03.012_bib82","series-title":"Investigation of Authenticity of \u05f3Claimed\u05f3 Randomized Controlled Trials (RCTs) and Quality Assessment of RCT Reports Published in China","author":"Wu","year":"2006"},{"key":"10.1016\/j.euroneuro.2014.03.012_bib83","first-page":"1","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","author":"Zhang","year":"2012","journal-title":"Int. J. Neuropsychopharmacol.\/Off. Sci. J. Coll. Int. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T07:03:04Z","timestamp":1565334184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0924977X14000972"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.012","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}